X

Trial Profile

A Phase I Multiple Ascending Dose Study of ASLAN002 (BMS 777607) in Subjects With Advanced or Metastatic Solid Tumours

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Apr 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BMS 777607 (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors ASLAN Pharmaceuticals

Most Recent Events

16 May 2018 Results published in the Investigational New Drugs
15 Feb 2017 Results published in an ASLAN Pharmaceuticals media release.
15 Feb 2017 According to an ASLAN Pharmaceuticals media release, new data from this phase 1 study of ASLAN002 (BMS777607) published in Science Translational Medicine journal.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com